Antitumor efficacy of radiation plus immunotherapy depends upon dendritic cell activation of effector CD8+ T cells.
Cheadle, Eleanor J
Illidge, Timothy M
AffiliationTargeted Therapy Group, School of Cancer and Enabling Sciences, University of Manchester
MetadataShow full item record
AbstractTumor cells dying after cytotoxic therapy are a potential source of antigen for T-cell priming. Antigen-presenting cells (APC) can cross-present MHC I-restricted peptides after the uptake of dying cells. Depending on the nature of the surrounding environmental signals, APCs then orchestrate a spectrum of responses ranging from immune activation to inhibition. Previously, we had demonstrated that combining radiation with either agonistic monoclonal antibody (mAb) to CD40 or a systemically administered TLR7 agonist could enhance CD8 T-cell-dependent protection against syngeneic murine lymphoma models. However, it remains unknown how individual APC populations affect this antitumor immune response. Using APC depletion models, we now show that dendritic cells (DC), but not macrophages or B cells, were responsible for the generation of long-term immunologic protection following combination therapy with radiotherapy and either agonistic CD40 mAb or systemic TLR7 agonist therapy. Novel immunotherapeutic approaches that augment antigen uptake and presentation by DCs may further enhance the generation of therapeutic antitumor immune responses, leading to improved outcomes after radiotherapy. Cancer Immunol Res; 4(7); 1-10. ©2016 AACR.
CitationAntitumor efficacy of radiation plus immunotherapy depends upon dendritic cell activation of effector CD8+ T cells. 2016: Cancer Immunol Res
JournalCancer Immunology Research
- Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
- Authors: Wiehagen KR, Girgis NM, Yamada DH, Smith AA, Chan SR, Grewal IS, Quigley M, Verona RI
- Issue date: 2017 Dec
- Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
- Authors: van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ
- Issue date: 2004 Dec 1
- The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
- Authors: Deronic A, Nilsson A, Thagesson M, Werchau D, Enell Smith K, Ellmark P
- Issue date: 2021 Dec
- Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
- Authors: Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE
- Issue date: 2005 Aug 1
- CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
- Authors: Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, Liu X, Liang Y, Peng H, Fu YX
- Issue date: 2017 Jan 1